Two Sigma Investments, LP Outlook Therapeutics, Inc. Transaction History

Two Sigma Investments, LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.22 - $0.66 $2,713 - $8,139	12,333 New	12,333 $4,000
Q2 2022 Aug 15, 2022	SELL	$0.91 - $2.01 $214,871 - $474,607	-236,123 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$1.22 - $2.03 $651,505 - $1.08 Million	-534,021 Reduced 69.34%	236,123 $420,000
Q4 2021 Feb 14, 2022	BUY	$1.27 - $2.23 $633,234 - $1.11 Million	498,610 Added 183.63%	770,144 $1.05 Million
Q3 2021 Nov 15, 2021	SELL	$2.12 - $2.76 $1.31 Million - $1.71 Million	-619,138 Reduced 69.51%	271,534 $589,000
Q2 2021 Aug 16, 2021	SELL	$1.78 - $2.76 $629,000 - $975,303	-353,371 Reduced 28.41%	890,672 $2.22 Million
Q1 2021 May 17, 2021	BUY	$0.94 - $3.31 $1 Million - $3.53 Million	1,066,429 Added 600.42%	1,244,043 $2.8 Million
Q4 2020 Feb 16, 2021	BUY	$0.7 - $1.58 $41,861 - $94,487	59,802 Added 50.76%	177,614 $231,000
Q3 2020 Nov 16, 2020	BUY	$0.61 - $1.6 $71,865 - $188,499	117,812 New	117,812 $85,000

31.5K

Ticker OTLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 226,144,992
Market Cap $1.17B
Description
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Investments, LP with notifications on news.